Medicenna to Present MDNA11 ABILITY-1 Trial Update and Novel MDNA113 Data at AACR 2025
核心洞察
Medicenna Therapeutics (搜索) will present interim results from its Phase 1/2 ABILITY-1 trial of MDNA11, the only long-acting 'beta-enhanced not-alpha' IL-2 super-agonist in clinical development for advanced solid tumors (搜索).
The company will also showcase preclinical data on MDNA113, a first-in-class tumor-targeted and tumor-activated bifunctional anti-PD1-IL2 Superkine designed to enhance therapeutic efficacy.
Both presentations will take place at the American Association for Cancer Research Annual Meeting in Chicago from April 25-30, 2025, highlighting Medicenna's expanding immunotherapy pipeline.
Medicenna Therapeutics (搜索) Corp. announced it will present new clinical and preclinical data from its innovative immunotherapy pipeline at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
The Toronto and Houston-based clinical-stage immunotherapy company will showcase two poster presentations highlighting advancements in its Superkine platform technology, which focuses on developing highly selective cytokine-based therapies for cancer and autoimmune diseases (搜索).
MDNA11 ABILITY-1 Trial Update
The first presentation will provide interim results from the ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with advanced solid tumors (搜索). MDNA11 represents a significant innovation in the immunotherapy landscape as the only long-acting, 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist currently in clinical development.
This engineered cytokine is designed with superior affinity toward CD122 (搜索) (IL-2 receptor beta) while eliminating CD25 (搜索) (IL-2 receptor alpha) binding. This selective targeting mechanism preferentially stimulates cancer-killing effector T cells and natural killer (NK) cells while avoiding the activation of immunosuppressive regulatory T cells, potentially offering improved efficacy and safety compared to conventional IL-2 therapies.
The poster presentation (Abstract CT047) is scheduled for Monday, April 28, 2025, from 9:00 AM to 12:00 PM in Poster Section 49.
Novel MDNA113 Preclinical Data
The second presentation will introduce preclinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bifunctional anti-PD1-IL2 Superkine. This innovative molecule combines checkpoint inhibition with cytokine stimulation in a single agent, designed to enhance therapeutic efficacy specifically within the tumor microenvironment.
MDNA113 represents an advancement in Medicenna's BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs, which aim to address the challenge of immunologically "cold" tumors that typically respond poorly to existing immunotherapies.
The poster (Abstract 7330) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM in Poster Section 40.
"These presentations at AACR 2025 highlight our continued progress in developing next-generation immunotherapies with the potential to overcome limitations of current treatment options," said a Medicenna representative. "Our Superkine platform enables us to engineer cytokines with enhanced selectivity and functionality, potentially offering improved efficacy and safety profiles for patients with cancer and autoimmune diseases (搜索)."
Expanding Immunotherapy Pipeline
Medicenna's pipeline extends beyond MDNA11 and MDNA113. The company's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent glioblastoma multiforme (搜索) (GBM (搜索)), an aggressive and typically fatal form of brain cancer. Bizaxofusp has received both FastTrack and Orphan Drug designations from the FDA and EMA, respectively.
Additionally, Medicenna is developing early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists from its MDNA209 platform as potential therapies for autoimmune and graft-versus-host diseases.
The company's approach to engineering highly selective versions of IL-2, IL-4, and IL-13 Superkines represents a significant advancement in cytokine-based therapies, which have historically been limited by toxicity and non-specific activation of immune cells.
Following the conclusion of the AACR 2025 Meeting, copies of both posters will be available on the "Events and Presentations" page of Medicenna's website for those unable to attend the conference.
Clinical Implications
The development of more selective cytokine-based therapies could address significant unmet needs in oncology. Traditional IL-2 therapy (aldesleukin) has demonstrated efficacy in certain cancers but is limited by severe toxicity and the activation of immunosuppressive regulatory T cells.
MDNA11's engineered selectivity may overcome these limitations by specifically activating anti-tumor immune cells while avoiding mechanisms that dampen immune responses. Similarly, MDNA113's bifunctional design could potentially enhance responses in tumors that have proven resistant to current immunotherapies by simultaneously blocking the PD-1 (搜索) immune checkpoint and delivering targeted IL-2 stimulation to the tumor microenvironment.
As the field of immunotherapy continues to evolve, engineered cytokines like those in Medicenna's pipeline represent a promising approach to expanding treatment options for patients with difficult-to-treat cancers.